TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas

Documenti analoghi

• Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2‐positive patients undergoing neoadjuvant therapy: A single‐institution retrospective cohort
  di: Min Xiong, et al.
  Pubblicazione: (2024)
• Trend analysis of hematological tumors in adolescents and young adults from 1990 to 2019 and predictive trends from 2020 to 2044: A Global Burden of Disease study
  di: Linlin Huang, et al.
  Pubblicazione: (2024)
• Outcomes of the transformation of follicular lymphoma to diffuse large B‐cell lymphoma in the rituximab era: A population‐based study
  di: Wenshuai Zheng, et al.
  Pubblicazione: (2024)
• Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single‐center experience
  di: Xiao He, et al.
  Pubblicazione: (2024)
• Neutrophil Elastase as a Prognostic Biomarker and Driver of Tumor Progression in Diffuse Large B‐Cell Lymphoma
  di: Xinyu Zheng, et al.
  Pubblicazione: (2026)